Clearside Biomedical, Inc. (CLSD) earnings
CLSD earnings moved a median of -1.36% by the close. Quarterly and annual CLSD reports and results, each read against the price at its own news timestamp. Back to the CLSD overview →
18 measured CLSD earnings events.
Where these CLSD earnings landedvs 18 measured CLSD earnings reactions
| Middle 50% of CLSD earnings reactions | -6.09% to +0.71% |
|---|---|
| Median reaction (to close) | -1.36% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 CLSD earnings events with a measured close landed between -6.09% and +0.71%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Clearside Biomedical, For: Sep 30 | SEC filing · Form 10-Q | -0.07% | -7.99% | |
| Form 10-Q Clearside Biomedical, For: Jun 30 | SEC filing · Form 10-Q | -0.25% | +2.54% | |
| Form 10-Q Clearside Biomedical, For: Mar 31 | SEC filing · Form 10-Q | -0.01% | +2.20% | |
| Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | -0.54% | |
| Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025 | Press release | +0.00% | +0.43% | |
| Form 10-K Clearside Biomedical, For: Dec 31 | SEC filing · Form 10-K | +3.06% | -3.06% | |
| Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -3.48% | -6.09% | |
| Form 10-Q Clearside Biomedical, For: Sep 30 | SEC filing · Form 10-Q | -3.48% | -6.09% | |
| Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 | Press release | +0.45% | -1.92% | |
| Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | +1.91% | +1.43% | |
| Form 10-Q Clearside Biomedical, For: Jun 30 | SEC filing · Form 10-Q | +1.91% | +1.43% | |
| Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024 | Press release | +0.89% | +0.00% | |
| Form 10-Q Clearside Biomedical, For: Mar 31 | SEC filing · Form 10-Q | +0.73% | -0.81% | |
| Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update | Press release | -1.53% | -3.85% | |
| Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 | Press release | +3.68% | +0.80% | |
| Form 10-K Clearside Biomedical, For: Dec 31 | SEC filing · Form 10-K | +2.87% | -6.32% | |
| Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | -6.73% | -8.77% | |
| Form 10-Q Clearside Biomedical, For: Sep 30 | SEC filing · Form 10-Q | -6.73% | -8.77% |
Keep exploring
More CLSD: analyst actions → · SEC filings → · CLSD overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Akari Therapeutics Plc - American Depositary Shares (AKTX) | 146 | 0.00% | 45% |
| BeyondSpring, Inc. - Ordinary Shares (BYSI) | 146 | 0.00% | 49% |
| Oramed Pharmaceuticals Inc. (ORMP) | 145 | +0.69% | 69% |
| GlycoMimetics, Inc. (GLYC) | 144 | +0.53% | 54% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.